Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2016-03-09, 10:34:25 | version 1.38.0
industry Implant Tribune U.S. Edition | February 2016 C12 Hans Geiselhöringer appointed new president of Nobel Biocare By Nobel Biocare Staff A s of Jan. 1, Hans Geiselhöringer has taken over as president of Nobel Biocare. The appoint- ment was made to strengthen the organization around its strategic goals. Since 2011, Geiselhöringer has served as executive vice president of global re- search, products and development, shap- ing a highly competitive product and innovation pipeline. Prior to that he was executive vice president global market- ing and products from 2010–2011 and head of NobelProcera and guided surgery from 2009–2010. Geiselhöringer joined Nobel Biocare as head of NobelProcera in 2008 and was appointed a member of the executive committee in 2009. From 2004 to 2009, Geiselhöringer act- ed as a global speaker for Nobel Biocare, and with this appointment, he becomes the first Nobel Biocare customer and dental expert in the company’s history to take the reigns as its highest ranking executive. In 1998, he founded DentalX GmbH, a leading dental laboratory chain specializ- ing in implantology, anaplastology, func- tional and esthetic reconstructions and imaging technologies. Geiselhöringer is a trained dental technician and possesses great technical knowledge of the implant and CAD/CAM industries, as well as deep customer understanding and insights, enabling continuity of innovation at Nobel Biocare. As a renowned expert on dental technologies and materials, he has published/co-published various clinical and research articles. He is also a member of numerous international dental associ- ations and a recognized lecturer at dental conventions throughout the world. “Our focus on the patient remains steadfast and constant. Everything we do will continue to be patient-centered, clinically relevant and evidence based,” Geiselhöringer said. “To strengthen our leadership in implant-based dentistry, we strongly focus on providing integrated digital solutions to improve the custom- er experience and increase productivity on all levels while ensuring a high level of clinical success and predictability. “With our counterparts at KaVo Kerr Group, we have all the pieces in place today, and we are grouping our highly skilled global teams together to form the industry’s new digital dentistry power- house. In summary, we at Nobel Biocare will continue our strong commitment to innovation, providing an ongoing pipe- line of superior solutions that helps more customers treat more patients better.” About Nobel Biocare Nobel Biocare is a world leader in the field of innovative implant-based den- tal restorations. The company’s portfo- lio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individual- ized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and NobelGuide®) and biomaterials (creos™). Nobel Biocare supports its customers through all phases of professional de- velopment, offering world-class train- ing and education along with practice support and patient information mate- rials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Prod- ucts and services are available in more than 80 countries through subsidiaries and distributors. Hans Geiselhöringer BIOLASE enters into development agreement with IPG Photonics By BIOLASE Staff B IOLASE, Inc., a global leader in dental lasers, announced recent- ly that it entered into a develop- ment and distribution agree- ment with IPG Photonics Corporation’s medical laser division, IPG Medical. IPG Photonics Corporation (“IPG”) pio- neered the development and commer- cialization of optical fiber-based lasers, creating a new generation of lasers with superior performance, reliability and lower costs, according to the company. IPG grew to become one of the world’s largest laser companies, opening up a myriad of industrial, manufacturing and medical applications using its unique fiber and semiconductor lasers. The development and distribution agreement between BIOLASE and IPG cov- ers several projects in various stages of development, with the expectation that these projects will culminate in commer- cialized joint dental laser products, acces- sories or integral system components. The parties will collaborate in the design and development of these new products and applications, with each party contributing their respective technological expertise, know-how and development resources. BIOLASE will be responsible for U.S. and international registrations of all dental products resulting from the agreement, and will have exclusive worldwide com- mercial distribution rights for certain products over a multi-year initial term af- ter completion of development. “We are extremely fortunate to part- ner with IPG, the world leader in fiber la- ser technology,” said Harold C. Flynn Jr., president and chief executive officer of BIOLASE. “This partnership brings with it significant opportunity to advance our product designs and our supply chain, ul- timately to provide a broader, deeper and more capable portfolio of laser-based solu- tions to dental practitioners globally. “This will advance efforts to fulfill our purpose, enabling clinicians to repair and restore patient’s dental conditions, while alleviating pain and reducing the anxiety commonly associated with invasive den- tal procedures,” added Flynn. “This partnership with BIOLASE fits very well with IPG’s strategic development and desire to build our medical application business. The parties will combine their expertise and capabilities to improve ex- isting and develop new dental laser ap- plications in markets with significant un- met clinical needs. BIOLASE’s established dental channels deepen our distribution capabilities in this area and leverage our patented dental laser technology and plat- forms,” said Dr. Gregory Altshuler, presi- dent of IPG Medical. About BIOLASE, Inc. BIOLASE, Inc., is a medical device compa- ny that develops, manufactures and mar- kets innovative lasers in dentistry and medicine and also markets and distrib- utes high-end 2-D and 3-D digital imaging equipment, CAD/CAM intraoral scanners and in-office milling machines and 3-D printers. BIOLASE’s products are focused on technologies that advance the practice of dentistry and medicine and offer ben- efits and value to health-care profession- als and their patients. The company’s proprietary laser prod- ucts incorporate approximately 250 patented and 100 patent-pending tech- nologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE asserts its products provide cutting-edge technology at competitive prices to de- liver the best results for dentists and pa- tients.